In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.
Vivasc Therapeutics Inc. has initiated work under a second National Institutes of Health (NIH) phase I STTR research grant, in conjunction with Georgetown University.
New treatments for cardiac hypertrophy, a thickening of the heart in response to pressure overload, could potentially treat or even reverse the condition after a new breakthrough discovery identified the mechanism that causes the heart's muscle to thicken, increasing the risk of irregular heart rhythms and heart failure.
